Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
His M&A background and experience with successful private-equity-backed companies will benefit the company’s growth and diversification strategy
Ryan has nearly 20 years of global legal and IP expertise in the pharmaceutical industry
CMOs showed an increasing reluctance to take on debt in 2022
Dr. Reddy's aims to roll out its trade generics across cities and towns in India
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Abbas will closely partner with CBC's business teams to identify, assess, and pursue investment opportunities and strategic acquisitions
Eris Lifesciences will be assigned the trademark of these brands by Dr. Reddy's for a consideration of Rs. 275 crore
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
Subscribe To Our Newsletter & Stay Updated
